Earnings Releases·Nov 5, 2026, 4:09 PM ET

Globus Medical — Third Quarter 2026 Earnings Summary

Worldwide net sales decreased 0.7% year-over-year to $763.7 million, while base business sales (excluding Nevro) rose 3.0%; GAAP net income and diluted EPS increased 18.7% and 18.2% respectively, driven by a 2.5 percentage point expansion in GAAP gross profit margins.
Full-year 2026 revenue guidance was raised to $3.09 billion (5.1% growth), with non-GAAP EPS guidance reaffirmed at $4.95–$5.05 (24.4%–26.9% growth), supported by eight consecutive quarters of sequential adjusted gross profit margin expansion.
The Board authorized a $500 million increase to the share repurchase program with no expiration date, while the company reported record quarterly operating and free cash flow generation.
Strategic momentum was highlighted by a 24% revenue increase in Enabling Technologies and a 73% rise in robot and navigation unit deployments, contrasting with a 2% growth in the U.S. Spine business and a 5.7% decline in international sales.